发布求助
文献互助 智能选刊 最新文献

Global and Regional Health Technology Assessment最新文献

筛选
英文 中文
A new payment-by-results method for determining the fair price of new oncological drugs 确定肿瘤新药公平价格的结果付费新方法
Global and Regional Health Technology Assessment Pub Date : 2015-07-10 DOI: 10.5301/GRHTA.5000198
E. Ballatori, L. Ferrante, B. Ruggeri, F. Roila
{"title":"A new payment-by-results method for determining the fair price of new oncological drugs","authors":"E. Ballatori, L. Ferrante, B. Ruggeri, F. Roila","doi":"10.5301/GRHTA.5000198","DOIUrl":"https://doi.org/10.5301/GRHTA.5000198","url":null,"abstract":"The high prices of new cancer drugs are likely to undermine national health services sustainability. As a solu tion to this problem, the “payment-by-results” method was proposed and nowadays this approach is commonly implemented by national drug agencies: the drug manufacturer is set to refund to the National Health Service the price of the drug if the benefits expected for the patient are not achieved. Based on the payment-by-results approach, we developed a new and easy to implement model, that can set a fair price, so that neither industry, nor National Health Service can obtain an undue gain. Obviously, this price can be modified by adjusting refund amounts to new healthcare and market conditions.","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115524998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Budget impact analysis of infliximab biosimilar: the Italian scenery 英夫利昔单抗生物仿制药预算影响分析:意大利风光
Global and Regional Health Technology Assessment Pub Date : 2015-07-10 DOI: 10.5301/GRHTA.5000194
C. Lucioni, S. Mazzi, R. Caporali
{"title":"Budget impact analysis of infliximab biosimilar: the Italian scenery","authors":"C. Lucioni, S. Mazzi, R. Caporali","doi":"10.5301/GRHTA.5000194","DOIUrl":"https://doi.org/10.5301/GRHTA.5000194","url":null,"abstract":"Chronic inflammatory diseases, while seriously impairing patients' quality of life, are a heavy financial cost to the National Health Service (NHS) and to society. The availability of biological drugs – among which infliximab (Remicade®) – greatly improved treatment efficacy. On the other hand, these drugs are an expensive resource. Infliximab patent protection is going to expire, and a biosimilar has been recently approved.A budget impact (BI) analysis was conducted to evaluate the favourable consequences – for the Italian NHS – of the biosimilar availability in terms of cost containment (savings), thanks to its lower price compared to the originator's. The analysis model expects that some patients in treatment with the originator will switch (according to a prudent assumption of the market uptake rate) to the biosimilar and that many naive patients will directly start treatment with the biosimilar (according to a bolder uptake rate assumed). Separately considering all the different diseases for which in...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"163 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127331129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Social cost of chronic pain in Italy 意大利慢性疼痛的社会成本
Global and Regional Health Technology Assessment Pub Date : 2015-03-17 DOI: 10.5301/GRHTA.5000187
M. Allegri, C. Lucioni, S. Mazzi, G. Serra
{"title":"Social cost of chronic pain in Italy","authors":"M. Allegri, C. Lucioni, S. Mazzi, G. Serra","doi":"10.5301/GRHTA.5000187","DOIUrl":"https://doi.org/10.5301/GRHTA.5000187","url":null,"abstract":"Chronic pain negatively impacts on sick people's daily life and their working ability, and it is a heavy financial burden on the health systems. This article is aimed at evaluating the social costs of chronic pain in Italy.The analysis is based on national tariffs and prices and on epidemiologic, health resource consumption, and absence from work published data; when no information specifically related to Italy was available, results from studies carried out in other European Countries were used as appropriate.The average annual cost per patient amounts to €4,556, 31% of which (€1,400) is charged on the National Health Service. Of this share, 51% is due to hospitalisation and 6% to analgesic drug (mostly NSAIDs) costs. Indirect costs (€3,157) are caused by sickness leaves (31%) and retirements.Based on an estimated prevalence of 8 million people with pain in Italy, the impact of chronic pain direct costs on public health expenditure results 9.6%, whereas the impact of total costs on gross domestic product...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"227 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124513002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Bevacizumab nel trattamento del carcinoma metastatico del colon-retto: l'RFOM nell'esperienza dell'A.O. Universitaria Senese 直肠癌转移性癌症治疗中的Bevacizumab:人工呼吸的rfom。Senese大学
Global and Regional Health Technology Assessment Pub Date : 2015-03-17 DOI: 10.5301/GRHTA.5000188
Davide Paoletti, Silvano Giorgi
{"title":"Bevacizumab nel trattamento del carcinoma metastatico del colon-retto: l'RFOM nell'esperienza dell'A.O. Universitaria Senese","authors":"Davide Paoletti, Silvano Giorgi","doi":"10.5301/GRHTA.5000188","DOIUrl":"https://doi.org/10.5301/GRHTA.5000188","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130928923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addendum all'articolo “Health Technology Assessment e vaccinazioni in Italia” 《意大利卫生技术评估与疫苗接种》附录
Global and Regional Health Technology Assessment Pub Date : 2015-03-17 DOI: 10.33393/grhta.2015.327
R. Gasparini
{"title":"Addendum all'articolo “Health Technology Assessment e vaccinazioni in Italia”","authors":"R. Gasparini","doi":"10.33393/grhta.2015.327","DOIUrl":"https://doi.org/10.33393/grhta.2015.327","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121189644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Pharmaceutical Sector is at Default Risk. A Proposal to Re-Establish the Economic Balance and Define a New Governance 制药行业面临违约风险。关于重建经济平衡和界定新治理的建议
Global and Regional Health Technology Assessment Pub Date : 2015-03-17 DOI: 10.5301/GRHTA.5000192
N. Martini
{"title":"The Pharmaceutical Sector is at Default Risk. A Proposal to Re-Establish the Economic Balance and Define a New Governance","authors":"N. Martini","doi":"10.5301/GRHTA.5000192","DOIUrl":"https://doi.org/10.5301/GRHTA.5000192","url":null,"abstract":"The pharmaceutical governance in Italy is provided by a cap applied as a percentage of the National Health Fund to the territorial (11.35%) and hospital expenditure (3.5%). The amount of overspending is charged to the pharmaceutical companies with a payback procedure. For the years 2014-2016 the overspending is estimated at about 3.8 billion euros, which is likely to result in a system default. In this article a new pharmaceutical governance is proposed and discussed; its aim is to avoid financial imbalance and to identify appropriate measures to bridge the gap between the very high prices of new/innovative drugs and the system sustainability.","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128218304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy 波纳替尼治疗意大利慢性髓性白血病的成本-效果
Global and Regional Health Technology Assessment Pub Date : 2015-03-17 DOI: 10.5301/GRHTA.5000189
C. Lucioni, S. Iannazzo, S. Mazzi, G. Saporiti, S. Chiroli
{"title":"Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy","authors":"C. Lucioni, S. Iannazzo, S. Mazzi, G. Saporiti, S. Chiroli","doi":"10.5301/GRHTA.5000189","DOIUrl":"https://doi.org/10.5301/GRHTA.5000189","url":null,"abstract":"An area-under-the-curve Markov model was designed to evaluate the cost-effectiveness of ponatinib as a third line treatment of Chronic Myeloid Leukemia-Chronic Phase (CML-CP) with reference to Italy. As for current guidelines, comparators were dasatinib, nilotinib, bosutinib, allogeneic stem cell transplantation (SCT), hydroxyurea. The economic perspective was the Italian National Health Service's (NHS), where costs for treatment drugs, monitoring and follow-up, adverse events, SCT procedure were considered on a lifetime span. Costs (mainly based on current tariffs in Italy) and benefits (QALYs) were discounted at a 3.5% annual rate. Ponatinib resulted dominant versus SCT. The lowest ICER was €13,090 (ponatinib vs hydroxyurea); the highest was €22,529 (ponatinib vs dasatinib). Sensitivity analysis – both deterministic (one way) and probabilistic – was focused on the comparison between ponatinib and dasatinib. The deterministic analysis showed that the most critical parameter in the model was ponatinib pri...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"188 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123352648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Budget impact of pneumococcal vaccination in adults and elderly in Italy 意大利成人和老年人肺炎球菌疫苗接种的预算影响
Global and Regional Health Technology Assessment Pub Date : 2015-03-13 DOI: 10.5301/GRHTA.5000193
F. Mennini, A. Marcellusi, P. Giannantoni, S. Valente, A. Rinaldi, E. Franco
{"title":"Budget impact of pneumococcal vaccination in adults and elderly in Italy","authors":"F. Mennini, A. Marcellusi, P. Giannantoni, S. Valente, A. Rinaldi, E. Franco","doi":"10.5301/GRHTA.5000193","DOIUrl":"https://doi.org/10.5301/GRHTA.5000193","url":null,"abstract":"BackgroundStreptococcus pneumoniae or pneumococcus, is responsible for severe invasive infections (IPD) in high risk groups and in the elderly. Moreover the pneumococcus is the most common cause of...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129237165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
‘Therapeutic Alternatives’: Procurement Rules for Drugs with Same Indication but without Equivalence Certification Released According to the Balduzzi Law “治疗替代品”:根据Balduzzi法发布的具有相同适应症但没有等效认证的药品采购规则
Global and Regional Health Technology Assessment Pub Date : 2015-03-07 DOI: 10.5301/GRHTA.5000202
A. Messori, V. Fadda, S. Trippoli
{"title":"‘Therapeutic Alternatives’: Procurement Rules for Drugs with Same Indication but without Equivalence Certification Released According to the Balduzzi Law","authors":"A. Messori, V. Fadda, S. Trippoli","doi":"10.5301/GRHTA.5000202","DOIUrl":"https://doi.org/10.5301/GRHTA.5000202","url":null,"abstract":"","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"73 14","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131898468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy 意大利精神分裂症患者棕榈酸帕利哌酮与长效利培酮维持治疗的成本-效果分析
Global and Regional Health Technology Assessment Pub Date : 2014-12-18 DOI: 10.5301/GRHTA.5000186
R. Ravasio, G. Nicolò, M. Vaggi
{"title":"Cost-effectiveness analysis of paliperidone palmitate versus long-acting risperidone as maintenance treatment in schizophrenia patients in Italy","authors":"R. Ravasio, G. Nicolò, M. Vaggi","doi":"10.5301/GRHTA.5000186","DOIUrl":"https://doi.org/10.5301/GRHTA.5000186","url":null,"abstract":"Objective\u0000To evaluate the cost-effectiveness of paliperidone palmitate (paliperidone long-acting injectable; PP) compared with long-acting injectable risperidone (RRP) in multi-episode patients (two or more relapses) with schizophrenia in Italy.\u0000Methods\u0000A pre-existing Markov model was utilized to simulate the history of a cohort of multi-episode patients transitioning through different health states on a monthly basis over a 12 or 24 month horizon from the perspective of the Italian National Health Service. Therapeutic strategies consisted of treatment with long-acting injectable risperidone (mean dose 37.5 mg every 2 weeks) or paliperidone palmitate (mean dose 75 mg equivalent [eq.] every month). Probability of relapse, level of adherence, side effects (extrapyramidal symptoms, tardive dyskinesia, weight gain and diabetes) and treatment discontinuation (switch) were derived from long-term observational data when feasible. The cost-effectiveness analysis considered quality adjusted life-years (QALYs) and direct medical costs. QALYs and costs (expressed in 2014 euro) were discounted at 3% annually. A one-way sensitivity analysis and a probabilistic sensitivity analysis were conducted.\u0000Results\u0000Paliperidone palmitate is the dominant long-acting injectable therapeutic option: a more effective (additional QALYs, less relapses) and less costly treatment option compared with long-acting injectable risperidone over a 12 or 24 month horizon. Results were robust when tested in sensitivity and probabilistic analyses.\u0000Conclusions\u0000Paliperidone palmitate was cost-saving from the Italian National Health Service perspective compared with long-acting injectable risperidone in the long-term treatment of multi-episode (two or more relapses) schizophrenia patients.","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131758119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信